Prof Fran Balkwill

Fran Balkwill

Deputy Lead, Centre for Tumour Microenvironment

Barts Cancer Institute
Queen Mary University of London
ORCID X

Research

cancer, tumour microenvironment, multi-cellular models, ovarian cancer, extracellular matrix, immunotherapy

Cancer Models

Interests

The interest and experience of my laboratory relates to complex multi-cellular models MCMs of the tumour microenvironment, especially in ovarian cancer. Having completed a multi-level deconstruction of ovarian cancer metastases, we have begun to reconstruct 3D multi-cellular models of these metastases using primary adipocytes, fibroblasts, mesothelial cells, monocytes and malignant cells. We are also currently working to vascularise these MCMs. We are using the models to understand cell cell communication in the tumour microenvironment, test new biological therapies and study sensitivity and resistance to T cell killing.

Grants

solid heart iconGrants of specific relevance to Predictive in vitro Models
solid heart iconREMODEL - ERC AdG 2021 Frances Balkwill
Fran Balkwill
£2,154,257 EPSRC - EU Scheme
01-10-2022 - 30-09-2027


solid heart iconEvaluation of the cytotoxic function of the AZ CAR-T cell products by employing human in vitro 3 D multicellar models of high grade serous ovarian cancer
Beatrice Malacrida and Fran Balkwill
£119,779 AstraZeneca UK Limited
12-09-2024 - 11-09-2025
bullet iconStudying immune repertoire as an indicator for response to immunotherapy treatment in High-grade serous ovarian cancer
Samar Mohamed Ibrahim Elorbany and Fran Balkwill
£24,208 CR-UK Cancer Research UK
15-02-2024 - 14-02-2025
bullet iconTargeting immune cells to improve response the chemotherapy in high-grade serous ovarian cancer
Samar Mohamed Ibrahim Elorbany and Fran Balkwill
£52,374 Barts and the London Charity
01-04-2023 - 31-03-2024
bullet iconCRUK City of London Centre 2020 Consumables Award
Fran Balkwill
£15,000 University College London
03-12-2020 - 31-03-2021
bullet iconCHILL COGNITION new version
Christopher Griffiths and Fran Balkwill
£302,743 Barts and the London Charity
01-09-2020 - 01-09-2024
bullet iconInterplay between ovarian cancer stem cells and the tumour microenvironment
Fran Balkwill
£230,324 Ovarian Cancer Research Alliance (USA)
01-01-2020 - 31-12-2023
bullet iconImmunotheraphy and clear cell ovarian cancer
Fran Balkwill
£290,799 MRC Medical Research Council
01-01-2019 - 30-06-2022
bullet iconThe effect of chemotherapy on Macrophage subpopulations in high-grade ovarian serous carcinoma
Fran Balkwill
£20,000 Wellbeing of Women
03-12-2018 - 30-11-2020
bullet iconTargeting the innate immune system in high grade serous ovarian cancer
Fran Balkwill
£1,924,190 CR-UK Cancer Research UK
01-10-2018 - 31-10-2024
bullet iconExploring novel immunotherapy combinations for the treatment of lung cancer- also look at Project 380880
Maria Castellano Sanchez and Fran Balkwill
£45,000 ACERTA
26-03-2018 - 15-03-2021
bullet iconAdvanced solid tissue models of T cell migration and activity
Fran Balkwill
£100,028 BBSRC Biotechnology and Biological Sciences Research Council
02-10-2017 - 25-03-2022
bullet iconAdvanced solid tissue models of T-cell migration and activity
Fran Balkwill
£32,000 GSK GlaxoSmithKline UK Ltd
01-10-2017 - 25-03-2022
bullet iconInvestigating the tumour extracellular matrix in the inhibition of anti-tumour imunity
Oliver Pearce and Fran Balkwill
£113,891 UCB Pharma SPRL
01-10-2017 - 28-02-2021
bullet iconTargeting the peritoneal tumour microenvironment of high grade serous ovarian cancer CIFG1C9R
Fran Balkwill
£1,652,914 CR-UK Cancer Research UK
01-08-2017 - 31-03-2019
bullet iconThe effects of neo-adjuvant chemotherapy on myleoid cells in high-grade serous ovarian cancer metastases CIFG1E4R
Fran Balkwill
£313,427 Wellcome Trust
01-05-2016 - 30-04-2019